Selected Start-Ups (6/01)
Executive Summary
In Vivo summarizes the technologies of several recently founded companies: Archemix Corp. will use its proprietary nucleic acid engineering technology to build protein detection chips and multiplexed assays for use in drug discovery. Gel-Del Technologies Inc. is developing protein-based biomaterials for making implanted medical devices more acceptable to the human body. Neuro Therapeutics Inc. was spun out of the University of British Columbia to commercialize therapies for stimulating repair of injured neurons after traumatic injury of the spinal cord or brain. OncoGenex Technologies Inc. aims to develop and commercialize therapeutics for hormone-independent prostate cancer. Rejuvenon Corp. aims to turn back the hands of time with drugs to treat or prevent disorders related to aging. A new entrant in the cardiovascular diagnostics arena, Belgium's Thermocore Medical Systems NV is developing a thermographic catheter-based system to localize and visualize unstable coronary plaque.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.